alcoholic fatty liver


Also found in: Dictionary, Thesaurus, Acronyms.
Related to alcoholic fatty liver: Alcoholic hepatitis

alcoholic fatty liver

A liver with acute and subacute (i.e., precirrhotic) changes induced by alcohol, a toxin that interferes with fatty acid oxidation, impairing the tricarboxylic acid cycle, resulting in incomplete beta-oxidation products from fatty acids.

alcoholic fatty liver

A liver with acute and subacute, ie precirrhotic, changes induced by alcohol, a toxin that interferes with fatty acid oxidation, impairing the tricarboxylic acid cycle, resulting in incomplete β-oxidation products from fatty acids. See Alcoholic cirrhosis. Cf Fatty liver of pregnancy.
Mentioned in ?
References in periodicals archive ?
Experimental study of osthol on treatment of hyperlipidemic and alcoholic fatty liver in animals.
Osthol regulates hepatic PPAR[alpha]-mediated lipogenic gene expression in alcoholic fatty liver murine
A review of the Non Alcoholic Fatty Liver Disease (NAFLD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline on the basis of route of administration and molecule type.
Identify and understand important and diverse types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD).
Research and Markets: Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2012
Scope of Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2015 covers: Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each; Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type; Listings of discontinued trials (suspended, withdrawn and terminated).
The report " Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Non Alcoholic Fatty Liver Disease.
Companies discussed in this Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2015 report include Conatus Pharmaceuticals Inc.
Non Alcoholic Fatty Liver Disease Pipeline and Clinical Trials Review H1 2015 Market Research Report
Our study suggests that resveratrol may serve as a promising agent for preventing or treating human alcoholic fatty liver disease," the authors concluded.
Resveratrol alleviates alcoholic fatty liver in mice.
Resveratrol may protect against alcoholic fatty liver disease
FIGURE 46 GLOBAL SALES OF OTHER DRUGS USED IN THE TREATMENT OF NON- ALCOHOLIC FATTY LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS) 127
Reportlinker Adds Liver Disease Treatments: The Global Market

Medical browser ?
Full browser ?